Morphine

Active ingredient: Morphine Sulfate

In short: Morphine Sulfate Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration an

Forms & strengthsMorphine Sulfate Injection, USP is a sterile, nonpyrogenic solution of morphine sulfate, free of antioxidants and preservatives to be administered by the intravenous route, available in the following dosage forms and strengths: •Single-dose ‎Carpuject™ …
LabelHospira, Inc.
Label updatedOct 16, 2026

What is Morphine used for?

Morphine Sulfate Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use:

Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy

, reserve opioid analgesics, including Morphine Sulfate Injection, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.

âš  Boxed warning (FDA's strongest warning)

Addiction, Abuse, and Misuse

Because the use of Morphine Sulfate Injection exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions .

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of Morphine Sulfate Injection, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of ‎Morphine Sulfate Injection are essential‎ .

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of Morphine Sulfate Injection and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate .

Neonatal Opioid Withdrawal Syndrome (NOWS)

Advise pregnant women using opioids

for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts ‎will be available at delivery .

Morphine dosage

•Morphine Sulfate Injection is for intravenous administration.

•Morphine Sulfate Injection is available in five concentrations as Carpuject™ cartridges for use with the Carpuject Holder ONLY, and in four concentrations as NexJect™ syringes for intravenous administration. Dosing errors can result in accidental overdose and death. Avoid dosing errors that may result from confusion between mg and mL and confusion with morphine injections of different concentrations when prescribing, dispensing, and administering Morphine Sulfate Injection. Ensure that the dose is communicated and dispensed accurately.

•Morphine Sulfate Injection should be prescribed only by healthcare ‎professionals who are knowledgeable about the use of opioids and how ‎to mitigate the associated risks.

•Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals . Because the risk of overdose increases as opioid doses ‎increase, reserve titration to higher doses of Morphine Sulfate Injection for ‎patients in whom lower doses are insufficiently effective and in whom the ‎expected benefits of using a higher dose opioid clearly outweigh the ‎substantial risks.‎

•Many acute pain conditions (e.g., the pain that occurs with a number ‎of surgical procedures or acute musculoskeletal injuries) require no ‎more than a few days of an opioid analgesic. Clinical guidelines on ‎opioid prescribing for some acute pain conditions are available.‎

•There is variability in the opioid analgesic dose and duration needed to ‎adequately manage pain due both to the cause of pain and to ‎individual patient factors. Initiate the dosing regimen for each patient individually, taking into account the patient's underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse .

•Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with Morphine Sulfate Injection. Consider this risk when selecting an initial dose and when making dose adjustments .

•Morphine must be injected slowly; rapid intravenous administration may result in chest wall rigidity.

•Inspect Morphine Sulfate Injection for particulate matter and discoloration prior to administration. Do not use if color is darker than pale yellow, if it is discolored in any other way, or if it contains a precipitate.

Direct Intravenous Injection

Use the lowest dose necessary to achieve adequate analgesia.‎

Adults: Initiate treatment in a dosing range of 0.1 mg to 0.2 mg per kg every 4 hours as needed to manage pain. Administer the injection slowly. …

How to take Morphine — instructions & advice from the label

Addiction, Abuse, and Misuse

Inform patients that the use of Morphine Sulfate Injection, even when taken as recommended, can result ‎in addiction, abuse, and misuse, which can lead to overdose and death . Instruct patients not to share Morphine Sulfate Injection with others and to take steps to protect ‎Morphine Sulfate Injection from theft or misuse.‎

Life-Threatening Respiratory Depression

Inform patients of the risk of life-threatening respiratory depression, including information that the risk is ‎greatest when starting Morphine Sulfate Injection or when the dosage is increased, and that it can occur ‎even at recommended dosages . ‎

Hyperalgesia and Allodynia

Advise patients to inform their healthcare provider if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain .‎

Serotonin Syndrome

Inform patients that opioids can cause a rare but potentially life-threatening condition called serotonin syndrome resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop after discharge from the hospital. …

Warnings & precautions

Do not take this medicine if: Morphine Sulfate Injection is contraindicated in patients with:

•Significant respiratory depression

•Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment

•Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days

•Known or suspected gastrointestinal obstruction, including paralytic ileus

•Hypersensitivity to morphine (e.g., anaphylaxis)

Morphine Sulfate Injection contains morphine, a Schedule II controlled substance. As an opioid, Morphine Sulfate Injection exposes users to the risks of addiction, abuse, and misuse .

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed Morphine Sulfate Injection. Addiction can occur at recommended dosages and if the drug is misused or abused. The risk of opioid-related overdose or overdose-related death is increased with higher opioid doses, and this risk persists over the course of therapy. In postmarketing studies, addiction, abuse, misuse, and fatal and non-fatal opioid overdose were observed in patients with long-term opioid use

.

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing Morphine Sulfate Injection, and monitor all patients receiving morphine sulfate for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. …

Morphine side effects

The following serious adverse reactions are described, or described in greater detail, in other sections:

•Addiction, Abuse, and Misuse

•Life-Threatening Respiratory Depression

•Interactions with Benzodiazepines or Other CNS Depressants

•Neonatal Opioid Withdrawal Syndrome

•Cardiovascular Instability

•Opioid-Induced Hyperalgesia and Allodynia

•Adrenal Insufficiency

•Severe Hypotension

•Gastrointestinal Adverse Reactions

•Seizures

•Withdrawal

The following adverse reactions associated with the use of morphine were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Serious adverse reactions associated with Morphine Sulfate Injection included respiratory depression, apnea, and to a lesser degree, circulatory depression, respiratory arrest, shock, and cardiac arrest. Rarely, anaphylactoid reactions have been reported when morphine or other phenanthrene alkaloids of opium are administered intravenously.

The most frequently observed adverse reactions included sedation, lightheadedness, dizziness, nausea, vomiting, constipation, and diaphoresis.

Other possible adverse reactions included:

Central Nervous System – Euphoria, dysphoria, weakness, headache, agitation, tremor, uncoordinated muscle movements, visual disturbances, transient hallucinations and disorientation. …

Drug interactions

Table 1 includes clinically significant drug interactions with Morphine Sulfate Injection.

Benzodiazepines and Other Central Nervous System (CNS) Depressants

Clinical Impact: | Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death ‎‎.

Intervention: | Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor patients closely for signs of respiratory depression and sedation.

Examples: | Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol.

Serotonergic Drugs

Clinical Impact: | The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.

Intervention: | If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue Morphine Sulfate Injection if serotonin syndrome is suspected. …

About this medicine

Morphine Sulfate Injection, USP is an opioid agonist, available in 2 mg/mL, 4 mg/mL, 8 mg/mL, 10 mg/mL, and 15 mg/mL (1 mL fill in 2.5 mL Carpuject™ Single‑dose cartridge with Luer Lock for the Carpuject™ Syringe System) and 2 mg/mL, 4 mg/mL, 8 mg/mL, and 10 mg/mL (1 mL fill in 1.5 mL NexJect™ Single-dose Prefilled Syringe with Luer Lock). When exposed to air it gradually loses water of hydration, and darkens on prolonged exposure to light. The chemical name is 7,8-Didehydro-4,5-epoxy-17-methyl-(5α,6α)-morphinan-3,6-diol sulfate (2: 1) (salt), pentahydrate, with the following chemical structure:

(C17H19NO3)2 • H2SO4 • 5H2O Molecular Weight is 758.83

Morphine sulfate USP is an odorless, white crystalline powder with a bitter taste. It has a solubility of 1 in 21 parts of water and 1 in 1000 parts of alcohol, but is practically insoluble in chloroform or ether. The octanol:water partition coefficient of morphine is 1.42 at physiologic pH and the pKa is 7.9 for the tertiary nitrogen (the majority is ionized at pH 7.4). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID be420e8b-bcb0-49b5-bb4d-1df8b9959809. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine